DYNE THERAPEUTICS INC

NASDAQ: DYN (Dyne Therapeutics, Inc.)

最近更新时间: 昨天, 9:33AM

20.35

-0.06 (-0.29%)

前收盘价格 20.41
收盘价格 20.33
成交量 876,831
平均成交量 (3个月) 2,916,911
市值 3,350,673,152
股市价格/股市净资产 (P/B) 4.28
52周波幅
6.36 (-68%) — 26.22 (28%)
利润日期 5 Nov 2025
稀释每股收益 (EPS TTM) -3.61
总债务/股东权益 (D/E MRQ) 3.49%
流动比率 (MRQ) 20.35
营业现金流 (OCF TTM) -319.72 M
杠杆自由现金流 (LFCF TTM) -176.84 M
资产报酬率 (ROA TTM) -39.92%
股东权益报酬率 (ROE TTM) -64.01%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 Dyne Therapeutics, Inc. 看涨 看跌

AIStockmoo 评分

0.0
分析师共识 1.5
内部交易活动 NA
价格波动 -3.5
技术平均移动指标 0.0
技术振荡指标 2.0
平均 0.00

相关股票

股票 市值 DY P/E(TTM) P/B
DYN 3 B - - 4.28
IONS 13 B - - 20.35
RNA 11 B - - 5.78
NUVL 8 B - - 9.71
CDTX 7 B - - 16.44
PCVX 6 B - - 2.18

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 0.56%
机构持股比例 110.24%

所有权

姓名 日期 持有股份
Atlas Venture Life Science Advisors, Llc 30 Sep 2025 9,130,465
Fcpm Iii Services B.V. 30 Sep 2025 5,462,846
Siren, L.L.C. 30 Sep 2025 4,729,174
52周波幅
6.36 (-68%) — 26.22 (28%)
目标价格波幅
17.00 (-16%) — 60.00 (194%)
60.00 (HC Wainwright & Co., 194.84%) 购买
38.50 (89.19%)
17.00 (JP Morgan, -16.46%) 保留
平均值 38.75 (90.42%)
总计 7 购买, 1 保留
平均价格@调整类型 19.35
公司 日期 目标价格 调整类型 价格@调整类型
Evercore ISI Group 15 Dec 2025 36.00 (76.90%) 购买 19.59
Stifel 11 Dec 2025 39.00 (91.65%) 购买 19.42
Oppenheimer 10 Dec 2025 40.00 (96.56%) 购买 19.69
12 Nov 2025 11.00 (-45.95%) 保留 18.61
Chardan Capital 09 Dec 2025 38.00 (86.73%) 购买 18.44
Morgan Stanley 09 Dec 2025 50.00 (145.70%) 购买 18.44
HC Wainwright & Co. 08 Dec 2025 60.00 (194.84%) 购买 22.20
06 Nov 2025 46.00 (126.04%) 购买 18.21
JP Morgan 14 Nov 2025 17.00 (-16.46%) 保留 18.79
RBC Capital 06 Nov 2025 30.00 (47.42%) 购买 18.21

该时间范围内无数据。

日期 类型 细节
23 Dec 2025 公告 Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
11 Dec 2025 公告 Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
09 Dec 2025 公告 Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
08 Dec 2025 公告 Dyne Therapeutics Announces Proposed Public Offering of Common Stock
08 Dec 2025 公告 Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
07 Dec 2025 公告 Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
05 Nov 2025 公告 Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
03 Nov 2025 公告 Dyne Therapeutics to Present at Upcoming Investor Conferences
06 Oct 2025 公告 Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
02 Oct 2025 公告 Dyne Therapeutics Appoints Brian Posner to its Board of Directors
29 Sep 2025 公告 Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票